Therapy of concomitant essential hypertension in patients with psoriasis: Clinical features and therapeutic approaches

Introduction. Psoriasis is a chronic immune-mediated skin disease, often accompanied by a large number of concomitant disorders, among which a special place is occupied by cardiovascular diseases. A vast number of scientific publications is devoted to the topic of psoriasis and cardiovascular comorbidities. The risk of cardiovascular dysfunction is 2 times higher in patients with psoriasis than in the population in general, just like the incidence of cardiac pathologies. European clinical guidelines urge to carry out cardiac screening in this group of patients to ensure timely prescription of appropriate therapy.

Aim. To study the effect of antihypertensive therapy on the course of psoriasis in patients with concomitant essential hypertension.

Materials and methods. We analysed medical records of 120 patients with psoriasis. They were divided into 2 groups. The first group had concomitant hypertension and the second group did not. Data from the medical records, physical examinations, consultations with GPs and cardiologists were reviewed.

Results. Our retrospective chart review of 120 patients with psoriasis showed that physicians most often prescribe to patients with essential hypertension (EH) the drugs that can provoke exacerbations of psoriasis. Also, patients with EH had more pronounced clinical manifestations of psoriasis, which could be explained by the impact of the cardiopathology itself and its drug therapy.

Conclusions. Given the features of comorbid disorders in psoriasis, the close collaboration of dermatologists and cardiologists is needed. In patients with psoriasis, routine cardiac screening, lifestyle changes and other measures aimed at reducing the risk of cardiovascular diseases are indicated. In the group of patients with concomitant essential hypertension, antihypertensive drugs with a relatively more favourable safety profile should be prescribed, for example calcium channel blockers, angiotensin II receptor blockers, imidazoline receptor agonists and diuretics.

1. Jindal S, Jindal N. Psoriasis and Cardiovascular Diseases: A Literature Review to Determine the Causal Relationship. Cureus. 2018;10(2):e2195. https://doi.org/10.7759/cureus.2195.

2. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945–1960. https://doi.org/10.1001/jama.2020.4006.

3. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https://doi.org/10.1136/bmj.m1590.

4. Orlando G, Molon B, Viola A, Alaibac M, Angioni R, Piaserico S. Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?. Front Immunol. 2022;13:868277. https://doi.org/10.3389/fimmu.2022.868277.

5. Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. Front Pharmacol. 2020;11:117. https://doi.org/10.3389/fphar.2020.00117.

6. Masson W, Lobo M, Molinero G. Psoriasis and Cardiovascular Risk: A Comprehensive Review. Adv Ther. 2020;37(5):2017–2033. https://doi.org/10.1007/s12325-020-01346-6.

7. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. https://doi.org/10.1093/eurheartj/ehab484.

8. Queiro R, Coto-Segura P, Braña I, Pino M, Burger S. Potential Differences in the Cardiometabolic Risk Profile of Patients with Psoriatic Disease according to Their HLA-C*06 Status. Biomed Res Int. 2022;2022:1451193. https://doi.org/10.1155/2022/1451193.

9. Sanchez DP, Sonthalia S. Koebner Phenomenon. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://pubmed.ncbi.nlm.nih.gov/31971748/.

10. Grželj J, Sollner Dolenc M. The role of xenobiotics in triggering psoriasis. Arch Toxicol. 2020;94(12):3959–3982. https://doi.org/10.1007/s00204-020-02870-8.

11. Awad VM, Sakhamuru S, Kambampati S, Wasim S, Malik BH. Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level. Cureus. 2020;12(7):e8964. https://doi.org/10.7759/cureus.8964.

12. Awad VM, Sakhamuru S, Kambampati S, Wasim S, Malik BH. Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level. Cureus. 2020;12(7):e8964. https://doi.org/10.7759/cureus.8964.

13. Lo Y, Tsai TF. Angiotensin converting enzyme and angiotensin converting enzyme inhibitors in dermatology: a narrative review. Expert Rev Clin Pharmacol. 2022;15(1):33–42. https://doi.org/10.1080/17512433.2022.2045950.

14. Almasood AA. Angiotensin-Converting Enzyme Inhibitor-Induced Psoriasis: A Case Report on Plaque Exacerbation. Cureus. 2024;16(9):e68556. https://doi.org/10.7759/cureus.68556.

15. Azzouz B, Morel A, Kanagaratnam L, Herlem E, Trenque T. Psoriasis After Exposure to Angiotensin-Converting Enzyme Inhibitors: French Pharmacovigilance Data and Review of the Literature. Drug Saf. 2019;42(12):1507–1513. https://doi.org/10.1007/s40264-019-00865-8.

16. Jin Q, Ren F, Song P. The association between ACE inhibitors and psoriasis based on the drug-targeted Mendelian randomization and real-world pharmacovigilance analyses. Expert Rev Clin Pharmacol. 2024;17(1):93–100. https://doi.org/10.1080/17512433.2023.2292605.

17. Song G, Kim JY, Yoon HY, Yee J, Gwak HS. A systematic review and meta-analysis of angiotensin-converting enzyme inhibitor use and psoriasis incidence. Sci Rep. 2021;11(1):10037. https://doi.org/10.1038/s41598-021-89490-z.

18. Azzouz B, Laugier-Castellan D, Sanchez-Pena P, Rouault M, Kanagaratnam L, Morel A, Trenque T. Calcium channel blocker exposure and psoriasis risk: Pharmacovigilance investigation and literature data. Therapie. 2021;76(1):5–11. https://doi.org/10.1016/j.therap.2020.05.013.

19. Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: A systematic review, meta- and network meta-analysis. Br J Clin Pharmacol. 2022;88(3):933–941. https://doi.org/10.1111/bcp.15060.

20. Letellier T, Leborgne F, Kerleau C, Gaultier A, Dantal J, Ville S. Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2020;15(12):1804–1813. https://doi.org/10.2215/CJN.02560220.

21. Azzouz B, Abou Taam M, Morel A, Trenque T. Psoriasis during angiotensin receptor blocker exposure: an underestimated adverse drug reaction. Expert Opin Drug Saf. 2018;17(9):853–857. https://doi.org/10.1080/14740338.2018.1508446.

22. Malik P, Pathania M, Rathaur VK. Chronic Plaque Psoriasis Exacerbated by Telmisartan Therapy: A Case Report. Int J Inn Res Med Sci. 2019;4(11):615–617. https://doi.org/10.23958/ijirms/vol04-i11/772/.

23. Klingberg E, Björkman S, Eliasson B, Larsson I, Bilberg A. Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. Arthritis Res Ther. 2020;22(1):254. https://doi.org/10.1186/s13075-020-02350-5.